Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. FDA. Valneva highlighted that it had completed recruitment for its pivotal late-stage trial, VLA1553-301, in April 2021 and expects to report topline data this summer. Source: Seeking Alpha 7/7/2021